Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas

NCT01380782 is registered in ClinicalTrials.gov with Patrick Y. Wen, MD as lead sponsor.

NCT NCT01380782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01380782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Lead sponsor
Patrick Y. Wen, MD
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
July 31, 2014
Enrollment
37 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma, gliosarcoma